Clinical Trials Details

Solid Tumors

A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of PG-11047 when Used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or

Trial ID: 05033

Contact: Muhammad Khan

Phone: (281)863-6538

Learn More about this trial.

go back | new search

This Study is currently being offered at the following Sites:

Practice	State/City
New York Oncology Hematology, P.C.	Albany, NY (Patroon)
New York Oncology Hematology, P.C.	Albany, NY (Scotland)
Texas Oncology, P.A.	Dallas, TX (Sammons TOPS)
Dayton Oncology & Hematology, P.A.	Dayton/Kettering, OH
Rocky Mountain Cancer Centers, LLP	Denver, CO (Midtown)
Greenville Hospital System, Clinical Research Unit	Greenville, SC (TOP)
Central Indiana Cancer Centers	Indianapolis, IN (E. County)
Central Indiana Cancer Centers	Indianapolis, IN (Rama)
Comprehensive Cancer Centers of Nevada	Las Vegas, NV (Twain)
Virginia Oncology Associates	Norfolk, VA (Lake Wright)
Cancer Centers of Florida, P.A.	Ocoee, FL
Texas Oncology, P.A.	Tyler, TX
Northwest Cancer Specialists, P.C.	Vancouver, WA (136th Ave)
Yakima Valley Memorial Hospital/North Star Lodge	Yakima, WA